Clinical Trial

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-30; most recent amendment 2026-02-04.
Status change: Not Yet Recruiting → Recruiting 2025-11-19
Trial Details
NCT Number NCT07107490
Lead Sponsor Chugai Pharmaceutical
Conditions Extensive Stage Small Cell Lung Cancer
Enrollment 122 participants
Start Date 2025-10-08
Primary Completion 2028-09-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-06